Ana Paula A.S. Ramos
Research Subjects
Research Interests
Ana Paula A.S. Ramos has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Angelo Borges de Melo Neto
Universidade Federal de Uberlândia/UFU
1 shared publication - Carolina Pereira de Souza Melo
Laboratório de Pesquisa translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna
1 shared publication - Fábio Ribeiro Queiroz
Laboratório de Pesquisa Translacional em Oncologia, Instituto Mário Penna, 30380-490 Belo Horizonte, MG, Brasil
1 shared publication - Jorge Gomes Goulart Ferreira
INSTITUTO MÁRIO PENNA
1 shared publication - Letícia da Conceição Braga
Pós-graduação em Genética, Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Belo Horizonte, MG, Brasil; Laboratório de Pesquisa Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, MG, Brasil
1 shared publication - Matheus de Souza Gomes
Laboratório de Bioinformática e Análise Molecular, Universidade Federal de Uberlândia (UFU), Campus Patos de Minas, Patos de Minas 38701-002, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (1) , e20240824
Validation of cervical cancer genetic signature in minimally invasive samples
Cervical cancer remains the leading cause of cancer death in 36 countries, and high-risk human papillomavirus types are responsible for most cases. Identifying strategies to make treatment more targeted and effective has become a priority. This study aims to validate a set of differentially expressed genes previously identified in cervical cancer stem cells as predictive biomarkers for response to chemoradiotherapy using minimally invasive samples. Additionally, it aims to elucidate the relationship between high-risk human papillomavirus infection and cervical cancer patients’ response to treatment. Gene expression for three differentially expressed genes (COPZ1, ILF2, and SNX2) was evaluated from 20 cervical cancer patients’ cervical cytology brushes. Unmapped reads from the same transcriptome were used to evaluate the presence of human papillomavirus in tumor tissue through qualitative screening of 13 high-risk human papillomavirus types. Our study did not clarify the relationship between high-risk human papillomavirus infection and the treatment response. However, we found downregulation of COPZ1 in patients who responded to treatment compared to non-responders, and ILF2 in patients with more advanced tumor stages. This suggests that COPZ1 and ILF2 expressions are potential cervical cancer prognostic biomarkers that can be assessed using samples commonly used in clinical practice.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (1) , e20240824
Open AccessValidation of cervical cancer genetic signature in minimally invasive samples
Cervical cancer remains the leading cause of cancer death in 36 countries, and high-risk human papillomavirus types are responsible for most cases. Identifying strategies to make treatment more targeted and effective has become a priority. This study aims to validate a set of differentially expressed genes previously identified in cervical cancer stem cells as predictive biomarkers for response to chemoradiotherapy using minimally invasive samples. Additionally, it aims to elucidate the relationship between high-risk human papillomavirus infection and cervical cancer patients’ response to treatment. Gene expression for three differentially expressed genes (COPZ1, ILF2, and SNX2) was evaluated from 20 cervical cancer patients’ cervical cytology brushes. Unmapped reads from the same transcriptome were used to evaluate the presence of human papillomavirus in tumor tissue through qualitative screening of 13 high-risk human papillomavirus types. Our study did not clarify the relationship between high-risk human papillomavirus infection and the treatment response. However, we found downregulation of COPZ1 in patients who responded to treatment compared to non-responders, and ILF2 in patients with more advanced tumor stages. This suggests that COPZ1 and ILF2 expressions are potential cervical cancer prognostic biomarkers that can be assessed using samples commonly used in clinical practice.